Ascendis Pharma AS (MEX:ASNDN) EBITDA Margin %: 9.45% (As of Mar. 2026)

What is Ascendis Pharma AS EBITDA Margin %?

Ascendis Pharma AS MEX:ASNDN 37 EBITDA Margin % is 9.45% as of Mar. 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Ascendis Pharma AS ranks better than 66.77% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ascendis Pharma AS's EBITDA for the three months ended in Mar. 2026 was MXN486 Mil. Ascendis Pharma AS's Revenue for the three months ended in Mar. 2026 was MXN5,141 Mil. Therefore, Ascendis Pharma AS's EBITDA margin for the quarter that ended in Mar. 2026 was 9.45%.

Ascendis Pharma AS (MEX:ASNDN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Ascendis Pharma AS EBITDA Margin % Related Terms

Ascendis Pharma AS EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS EBITDA Margin % Chart

Ascendis Pharma AS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-4,688.13

-1,034.07

-154.16

-79.76

-15.87

Ascendis Pharma AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-43.82	1.47	-15.74	-0.54	9.45

MEX:ASNDN vs SMMT, BBIO, JAZZ: EBITDA Margin % Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's EBITDA Margin % falls into.

Save Embed

37GF Score

Ascendis Pharma AS MEX:ASNDN

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ascendis Pharma AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Ascendis Pharma AS's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-2410.065	/	15183.233
	=	-15.87 %

Ascendis Pharma AS's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	485.695	/	5140.904
	=	9.45 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 9.45% mean?

Ascendis Pharma AS (MEX:ASNDN) has a EBITDA Margin % of 9.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #314 out of 945 companies in the Biotechnology industry, placing it in the top 33.2%.

Is Ascendis Pharma AS's EBITDA Margin % too high?

Ascendis Pharma AS's current EBITDA Margin % is 9.45%. Based on the distribution chart, Ascendis Pharma AS ranks #314 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.

How does Ascendis Pharma AS's EBITDA Margin % compare to SMMT and BBIO?

According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #314 out of 945 companies for EBITDA Margin %. This puts Ascendis Pharma AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current EBITDA Margin % is 9.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ascendis Pharma AS stock overvalued right now?

Ascendis Pharma AS (MEX:ASNDN) has a current EBITDA Margin % of 9.45%. The current EBITDA Margin % is 9.45%. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current EBITDA Margin % is 9.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Industry Healthcare Biotechnology

Comparable Companies SMMT BBIO JAZZ EXEL IONS AXSM MDGL BMRN ARWR CYTK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ASND:USA

Address Tuborg Boulevard 12, Hellerup, DNK, 2900

Website https://www.ascendispharma.com

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

37GF Score

Get the complete analysis for MEX:ASNDN

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44

Price

View MEX:ASNDN Analysis

See EBITDA Margin % data for all stocks →